Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Virginiamycin S1 is a cyclodepsipeptide antibiotic and one of the two major components of the streptogramin antibiotic complex known as virginiamycin, which is produced by various Streptomyces species including Streptomyces virginiae. It belongs to the streptogramin B group and acts as a macrolide antibiotic. Virginiamycin S1 inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit at the peptidyl transferase center, thereby blocking aminoacyl-tRNA binding and peptide bond formation. This action disrupts protein synthesis in gram-positive bacteria, leading to bacteriostatic or bactericidal effects depending on context. Virginiamycin (as a mixture of M1 and S1) is used primarily in veterinary medicine for treating infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry. It also finds use in industrial fermentation processes such as bioethanol production to prevent microbial contamination[2][3][4][5][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on virginiamycin S1.